SGLT-2 inhibitors and GLP-1 receptor agonists for Type 2 diabetes

被引：0
|
作者：
Davila, Esteban [1 ]
Mccormack, James [2 ]
机构：
[1] New York City Hlth Hosp Kings Cty, Dept Emergency Med, 451 Clarkson Ave, Brooklyn, NY 11203 USA
[2] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada
来源：
ACADEMIC EMERGENCY MEDICINE | 2024年 / 31卷 / 04期
关键词：
diabetes; GLP-1 receptor agonist; metformin; SGLT-2; inhibitor;
D O I：
10.1111/acem.14895
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
[No abstract available]
引用
收藏
页码：408 / 411
页数：4
相关论文
共 50 条
  • [41] Lipid Profile Changes Associated with SGLT-2 Inhibitors and GLP-1 Agonists in Diabetes and Metabolic Syndrome
    Premji, Resmi
    Nylen, Eric S.
    Naser, Nejat
    Gandhi, Shruti
    Burman, Kenneth D.
    Sen, Sabyasachi
    METABOLIC SYNDROME AND RELATED DISORDERS, 2022, 20 (06) : 321 - 328
  • [42] Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT-2 inhibitors in adult patients with type 2 diabetes: a systematic review
    Gonzalez-Gonzalez, Jose Gerardo
    Diaz Gonzalez-Colmenero, Alejandro
    Millan-Alanis, Juan Manuel
    Lytvyn, Lyubov
    Solis, Ricardo Cesar
    Mustafa, Reem A.
    Palmer, Suetonia C.
    Li, Sheyu
    Hao, Qiukui
    Alvarez-Villalobos, Neri Alejandro
    Vandvik, Per Olav
    Rodriguez-Gutierrez, Rene
    BMJ OPEN, 2021, 11 (07):
  • [43] Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes
    Lajara, Rosemarie
    POSTGRADUATE MEDICINE, 2019, 131 (08) : 555 - 565
  • [44] Review: In type 2 diabetes, SGLT-2 inhibitors or GLP-1 agonists reduce mortality vs control or DPP-4 inhibitors
    Egan, Aoife M.
    Montori, Victor M.
    ANNALS OF INTERNAL MEDICINE, 2018, 169 (02) : JC2 - JC2
  • [45] GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off
    Dario Giugliano
    Lorenzo Scappaticcio
    Miriam Longo
    Giuseppe Bellastella
    Katherine Esposito
    Cardiovascular Diabetology, 20
  • [46] Renoprotective effects of GLP-1 receptor agonists and SGLT-2 inhibitors-is hemodynamics the key point?
    Lee, Blaire
    Holstein-Rathlou, Niels-Henrik
    Sosnovtseva, Olga
    Sorensen, Charlotte M.
    AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2023, 325 (01): : C243 - C256
  • [47] Relevance of GLP-1 receptor agonists or SGLT-2 inhibitors on the recruitment for clinical studies in patients with NAFLD
    Holzhey, Michael
    Petroff, David
    Wirkner, Kerstin
    Engel, Christoph
    Baber, Ronny
    Toenjes, Anke
    Zeynalova, Samira
    Yahiaoui-Doktor, Maryam
    Berg, Thomas
    Karlas, Thomas
    Wiegand, Johannes
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2024, 36 (01) : 107 - 112
  • [48] GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off
    Giugliano, Dario
    Scappaticcio, Lorenzo
    Longo, Miriam
    Bellastella, Giuseppe
    Esposito, Katherine
    CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
  • [49] SGLT-2 Inhibitors' and GLP-1 Receptor Agonists' Influence on Neuronal and Glial Damage in Experimental Stroke
    Murasheva, Anna
    Fuks, Oksana
    Timkina, Natalya
    Mikhailova, Arina
    Vlasov, Timur
    Samochernykh, Konstantin
    Karonova, Tatiana
    BIOMEDICINES, 2024, 12 (12)
  • [50] SGLT2 Inhibitors or GLP-1 Receptor Agonists Reduce Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Shaughnessy, Allen F.
    AMERICAN FAMILY PHYSICIAN, 2021, 104 (02) : 206 - 206
12345